Evidence map›Paper›PMID 36718131›Full record

ArticleJournal of herbal medicine2023

Ali Nadi, Amir Abbas Shiravi, Zahra Mohammadi, Amin Aslani, Mehrdad Zeinalian

Open access · greenAbstract read
In one paragraph

Article in Journal of herbal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. The Antiviral Potential ofMolecules (Basel, Switzerland) · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Natural solutions for glowing skin: spices.Frontiers in nutrition · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ali NadiSchool of Nutrition and Food Sciences, Isfahan University of Medical sciences, Isfahan, Iran.
Amir Abbas ShiraviDepartment of Genetics and Molecular biology, School of Medicine, Isfahan University of Medical sciences, Isfahan, Iran.
Zahra MohammadiDepartment of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
Amin AslaniDepartment of Genetics and Molecular biology, School of Medicine, Isfahan University of Medical sciences, Isfahan, Iran.
Mehrdad ZeinalianDepartment of Genetics and Molecular biology, School of Medicine, Isfahan University of Medical sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRShahid Bahonar University of Kerman · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A worldwide pandemic infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a deadly disease called COVID-19. Interaction of the virus and the Angiotensin converting-enzyme 2 (ACE2) receptor leads to an inflammatory-induced tissue damage. Method: This is a narrative review in which using PubMed, Scopus, ISI, Cochrane, ScienceDirect, Google scholar, and Arxiv preprint databases, the molecular mechanisms of therapeutic and protective effects of TvL and its active compounds have been discussed regarding the molecular pathogenesis in COVID-19. Results: Thyme could suppress TNF-alpha, IL-6, and other inflammatory cytokines. It also enhances the anti-inflammatory cytokines like TGF-beta and IL-10. Thyme extract acts also as an inhibitor of cytokines IL-1-beta and IL-8, at both mRNA and protein levels. Thymol may also control the progression of neuro-inflammation toward neurological disease by reducing some factors. Thyme and its active ingredients, especially Thymol and Carvacrol, have also positive effects on the renin-angiotensin system (RAS) and intestinal microbiota. Conclusions: Accordingly, TvL and its bioactive components may prevent COVID-19 complications and has a potential protective role against the deleterious consequences of the disease.

Indexed as

ACE2, angiotensin-converting enzyme IIACE, angiotensin-converting enzymeACEIs, ACE inhibitorsALI, acute lung injuryAngII, angiotensin IIARBs, angiotensin receptor blockersARDS, acute respiratory distress syndromeAT1R, angiotensin II receptor type 1BALF, brochalveolar lavage fluidCOVID-19CVD, cardio vascular diseaseIL, InterleukinInfectionRAS, renin-angiotensin systemSARS-COV2TGF-β, Transforming growth factor betaTh, T helperThymeThymus vulgaris LTMPRSS2, transmembrane serine protease 2TNF, tumor necrosis factorTreatmentTvL, Thymus vulgaris L.

Identifiers

PMID36718131
PMCPMC9877322
OpenAlexW4318671871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.